StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Saturday. The firm issued a sell rating on the stock.

CTLT has been the subject of a number of other research reports. Stephens restated an equal weight rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reissued a sector perform rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. UBS Group reissued a neutral rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Barclays boosted their price objective on shares of Catalent from $45.00 to $47.00 and gave the company an equal weight rating in a research report on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Hold and a consensus target price of $52.46.

Catalent Stock Performance

Shares of CTLT opened at $56.30 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The stock has a market cap of $10.19 billion, a P/E ratio of -8.28, a PEG ratio of 6.03 and a beta of 1.20. The company has a 50-day moving average of $56.65 and a two-hundred day moving average of $48.78. Catalent has a 12-month low of $31.45 and a 12-month high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business’s revenue was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. As a group, research analysts predict that Catalent will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Catalent

Institutional investors and hedge funds have recently bought and sold shares of the stock. Thompson Siegel & Walmsley LLC increased its position in Catalent by 46.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock worth $32,069,000 after purchasing an additional 223,944 shares during the last quarter. Vanguard Group Inc. increased its position in Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after purchasing an additional 365,648 shares during the last quarter. Tran Capital Management L.P. increased its position in Catalent by 12.2% during the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after purchasing an additional 39,208 shares during the last quarter. Hsbc Holdings PLC grew its stake in Catalent by 43.1% during the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock worth $8,803,000 after buying an additional 58,240 shares during the period. Finally, SG Americas Securities LLC grew its stake in Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.